Mycovia Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Mycovia Pharmaceuticals's estimated annual revenue is currently $5.8M per year.
- Mycovia Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Mycovia Pharmaceuticals has 29 Employees.
- Mycovia Pharmaceuticals grew their employee count by -43% last year.
Mycovia Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO & Board Director | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | Chief Development Officer | Reveal Email/Phone |
4 | Chief Strategy Officer | Reveal Email/Phone |
5 | SVP Finance, Administration and Treasurer | Reveal Email/Phone |
6 | VP Operations | Reveal Email/Phone |
7 | VP Medical Affairs | Reveal Email/Phone |
8 | VP Value Access and Trade | Reveal Email/Phone |
9 | VP, Sales | Reveal Email/Phone |
10 | Senior Director Pharmaceutical Development | Reveal Email/Phone |
Mycovia Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.8M | 29 | 4% | N/A | N/A |
#2 | $3.2M | 16 | 0% | N/A | N/A |
#3 | $83.2M | 414 | 7% | N/A | N/A |
#4 | $31M | 154 | 56% | N/A | N/A |
#5 | $66.6M | 265 | 0% | $35M | N/A |
#6 | $10.9M | 54 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -6% | N/A | N/A |
#8 | $165.7M | 216 | 14% | $250.7M | N/A |
#9 | $26.5M | 132 | -11% | $637.8K | N/A |
#10 | $49.4M | 246 | 6% | N/A | N/A |
What Is Mycovia Pharmaceuticals?
Mycovia Pharmaceuticals was formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. At Mycovia, we are passionate about developing breakthrough therapies in women’s health and dermatology. Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a yeast infection that affects millions of women each year and often leads to distressing physical discomfort and a negative impact on psychological well-being. In studies to date, VT-1161 has demonstrated a high degree of potency against the organisms that cause RVVC. It may also have a lesser tendency to induce drug resistance and the variety of side effects that limit the use of currently available oral antifungal therapies. We are conducting global Phase 3 clinical trials in RVVC. VT-1161 has also been studied in onychomycosis, a fungal infection of the nail which affects approximately 35 million people in the United States and millions more around the globe. Onychomycosis can be a significant medical issue particularly for diabetics or other patients with compromised immune systems or poor circulation of the lower extremities.
keywords:N/AN/A
Total Funding
29
Number of Employees
$5.8M
Revenue (est)
-43%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.1M | 29 | 0% | N/A |
#2 | $7.5M | 29 | -15% | $50.1M |
#3 | $4.3M | 29 | -9% | N/A |
#4 | N/A | 29 | 32% | N/A |
#5 | $2M | 29 | 16% | N/A |